Terminated PHASE3 INTERVENTIONAL NCT00273338

DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])

A Phase 3, Randomized, Open-Label Study Evaluating DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (ASCENT-2)

Sponsor: Novacea

Conditions Prostate Cancer

Interventions calcitriol docetaxel

Updated 7 times since 2017 Last updated: Nov 2, 2007 Started: Jan 31, 2006 Completion: Nov 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

DSMB

Listed as NCT00273338, this PHASE3 trial focuses on Prostate Cancer and remains terminated or withdrawn. Sponsored by Novacea, it has been updated 7 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Terminated PHASE3
Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE3

First recorded

Jan 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novacea

Data source: Novacea

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

14529 Cortez Blvd., United States , Abilene, United States , Albany, United States , Alexandria, United States , Amarillo, United States , Anchorage, United States , Arad, Romania , Arlington, United States , Athens, United States , Atlanta, United States and 178 more locations